(MRNA) Moderna Inc
October 12, 2021 at 11.30am
A clinical stage biotechnology company, based in Cambridge, Massachusetts, Moderna focuses on drug discovery, drug development and vaccine technologies based on messenger ribonucleic acid (mRNA) for the treatment of infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, oncology and rare genetic diseases.
One of the forerunners in the COVID-19 vaccine, Moderna’s candidate mRNA-1273 had shown preliminary evidence of 94% efficacy in preventing the disease in a Phase III trial, with only minor flu-like side effects. As a result, it received Emergency Use Authorisation (EUA) in Europe, the U.S. and Canada, while as of January 2021, it has been authorised for use in the U.K.